Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)
Complete Title: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Trial Phase: I
Investigator: Jennifer Specht, MD
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.
Keywords:
- Cervical Cancer
- Endometrial Cancer
- Melanoma
- Nasopharyngeal Cancer
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Carcinoma, Squamous Cell
- Carcinoma, Hepatocellular
- Urothelial Cancer
- Carcinoma, Small Cell
- Carcinoma, Renal Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Jennifer Specht, MD
RG1004763
NCT03752398
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Cervical Cancer
Endometrial Cancer
Melanoma
Nasopharyngeal Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Carcinoma, Squamous Cell
Carcinoma, Hepatocellular
Urothelial Cancer
Carcinoma, Small Cell
Carcinoma, Renal Cell